Introduction
Chemo-resistance and cancer relapse represent significant challenges in cancer management, and are attributable in part to the presence of subpopulations of cancer cells termed cancer stem cells (CSC) or tumor-initiating cells. CSC were first identified in acute myeloid leukemia (1, 2) and are operationally defined by their self-renewal and tumor initiation capacities. The presence of CSC in solid tumors was first described in breast cancer (3) and has since been identified in a wide variety of solid tumors, and implicated in resistance to anticancer therapies, cancer recurrence, and metastasis. (4-7)
The phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is one of the most frequently activated signaling pathways in cancer, playing a central role in tumorigenesis by regulating the proliferation, survival, differentiation and migration of cancer cells as well as tumor angiogenesis (8) . AKT and mTOR are the major effector kinases in the PI3K/mTOR pathway. mTOR exists in two distinct protein complexes, mTORC1 and mTORC2, each with different downstream substrates (9) . The PI3K/mTOR pathway also plays a role in cancer stem cells (8, (10) (11) (12) (13) (14) . Activation of the PI3K/mTOR pathway in adult blood cells through PTEN deletion led to the generation of leukemia-initiating cells (11). Similarly, activation of PI3K/mTOR signaling, achieved by knocking down PTEN, enriched breast cancer stem cells (13) .
VS-5584 is a highly potent and selective dual PI3K/mTOR inhibitor, exhibiting approximately equal low nanomolar potency against mTOR kinase and all four Class I isoforms of PI3K. VS-5584 was shown to target the mTORC1 and mTORC2 complexes as well as PI3K in cells, as evidenced by inhibition of phosphorylation of cellular targets of these kinases including AKT (Ser473 and Thr308) and ribosomal protein S6 (Ser240/244) (15) . VS-5584 Kolev et al. shows no significant inhibitory activity against over 400 other protein and lipid kinases, including closely related lipid kinases such as DNA-PK and VSP34, underscoring the high selectivity of VS-5584 (15) . Simultaneous inhibition of mTORC1/2 and PI3K by VS-5584 is expected to more effectively shut down PI3K/mTOR signaling than isoform-selective PI3K or mTOR inhibitors that block only a subset of these targets. This approach should also overcome the feedback activation of PI3K signaling that is thought to limit the effectiveness of rapamycin analogs (8, 9) . It was reported recently that activation of mTOR accounted for the resistance of breast cancer to the PI3Kα−selective inhibitor BYL719 in the clinic, further arguing the importance of simultaneous inhibition of mTOR and PI3K (16) .
Here we report that in addition to exhibiting potent anti-cancer activity in a broad set of tumor models, VS-5584 preferentially targets CSC as demonstrated using a panel of orthogonal CSC assays, including the limiting dilution tumor-initiating assay, a gold standard for CSC.
Consistent with the observation that VS-5584 preferentially abolishes CSC, VS-5584 delayed tumor regrowth in small cell lung xenograft models after cessation of treatment with cisplatin.
These results provide compelling rationale for the clinical development of VS-5584 as a cancer stem cell targeting agent.
Materials and Methods

Cell lines, primary human tumor tissues, compounds and reagents
All cancer cell lines used were obtained from ATCC (Manassas, VA) with the exception of SUM159 which was acquired from Asterand (Detroit, MI). Cell lines were authenticated by STR (short tandem repeat) analysis at either ATCC or IDEXX Radil (Columbia, MO). and maintained as described (17) . Primary human breast and ovarian tumor specimens were obtained from Tissue Solutions Ltd. (Glasgow, UK) after patient's consent and institutional IRB approval. VS-5584 was synthesized by S*Bio (15) . Other compounds were purchased from Selleckchem (Munich, Germany). Reverse-Phase Protein Microarray (RPMA) was conducted at Theranostics Health Inc (Rockville, MA).
Aldefluor assays
An imaging-based Aldefluor assay was conducted using the Aldefluor assay kit (STEMCELL Technologies, Vancouver, BC) with the following modifications: Cells were plated in collagen treated plates. Following compound treatment, Aldefluor reagents supplemented with 10 ng/ml Hoechst 33342 dye were added. Plates were incubated at 37⁰C for 20 min. After washing, Aldefluor+ and total cells (in buffer containing Hoechst 33342) were quantified using Celigo (Nexcelom Bioscience, Lawrence, MA). ALDH inhibitor diethylamino benzaldehyde (DEAB) treated cells were used as a negative control. FACS-based Aldefluor assay was conducted following manufacturer's instructions (STEMCELL Technologies).
Side Population (SP) assays
Hoechst 33342 exclusion (Side Population) assay was carried out as previously described (18) .
HMLER assay
HMLER cells were treated with compounds for 4 days. Following a 4-day compound wash-off and cell recovery period, cells were stained with PE-labeled anti-CD24, APC-labeled anti-CD44 antibody (BD Biosciences) and 7-AAD+ live cells were subject to FACS analysis. 
Tumorsphere assay
To determine tumorsphere forming efficiency, cells from tissue culture or dissociated tumors were plated in tumorsphere forming medium as previously described (17) . Spheres were enumerated using Celigo.
Apoptosis assays and siRNA transfection
Standard methods were used for Annexin V and Caspsase 3/7 assays and siRNA transfection with details in Supplementary Materials and Methods. Author Manuscript Published OnlineFirst on November 28, 2014; DOI: 10.1158/0008-5472.CAN- or subcutaneously (NCI-H841 tumors) of immunodeficient SHrN mice (Harlan). Tumorinitiating frequency (TIF) was calculated using the ELDA Software (19) .
In vivo Tumor xenograft studies, cell dissociation and limiting dilution assay
Results
Preferential targeting of cancer stem cells by VS-5584 in vitro.
In a previous screening of over 300,000 compounds using an HMLE CSC assay (17) , a number of PI3K/mTOR pathway inhibitors were found to preferentially target CSC. This historical observation prompted our initial interest in exploring the PI3K/mTOR pathway to target CSC. We therefore determined the effect of VS-5584, a highly potent and selective dual inhibitor of PI3K/mTOR (15), on CSC in multiple orthogonal CSC assays that have been validated by limiting dilution implantation in mice.
Cancer stem cells have high aldehyde dehydrogenase (ALDH) activity, which can be measured by the Aldefluor enzymatic assay (20) . Aldefluor+ cells from several breast cancer cell lines have been shown to display CSC characteristics (21) . We also show that Aldefluor+ SUM159 triple negative breast cancer cells display enhanced self-renewal and tumor-initiating capability relative to Aldefluor-cells in immunodeficient mice (Fig. S1 ). To quantify CSC that harbor high ALDH activity, we developed an imaging-based Aldefluor assay. As shown in tumor cells across these cell lines. In contrast, exposure to the cytotoxic agents paclitaxel or cisplatin, increased the percentage of Aldefluor+ cells (Fig. 1B) , consistent with CSC being resistant to conventional chemotherapy. Importantly, VS-5584 attenuated paclitaxel-induced enrichment of Aldefluor+ cells (Fig. 1C) .
A tumorsphere assay can be used to measure self-renewal of CSC (22) . SUM159 and MCF-7 tumorspheres were treated with VS-5584, paclitaxel, or combination of both agents, and the effect of these treatments on CSC was determined in a secondary tumorsphere assay.
Tumorsphere forming efficiency was decreased by VS-5584 but increased by paclitaxel.
Strikingly, combination of VS-5584 and paclitaxel almost completely abolished tumorsphere formation, indicating a marked reduction of CSC (Fig. 1D ).
Enhanced drug efflux is another attribute of CSC. Thus CSC, when assayed by their ability to exclude the Hoechst 33342 dye, are found to reside in a side population (SP) with greater dye exclusion capacity (18) . As with the Aldefluor assay, we first validated that SP of SUM159 cells indeed exhibited elevated tumor-initiating capability relative to non-SP ( (Fig. 3D-F) .
Since VS-5584 inhibits multiple nodes of the PI3K/mTOR signaling pathway, we reasoned that inhibition of CSC by VS-5584 might involve effects on more than one of these pathway components. To test this hypothesis, we investigated effects of the potent mTORC1 inhibitor everolimus on CSC in the same MCF7 xenograft model. In contrast to VS-5584, oral daily dosing of everolimus at 5 mg/kg, shown to inhibit mTORC1 activity in tumors as evidenced by reduction of S6 phosphorylation (Fig. 3G) , did not reduce the proportion of CSC, as measured by multiple assays (Fig. 3D-F) . Collectively, these data suggest that inhibition of components of the PI3K/mTOR pathway other than mTORC1 might be important for the preferential reduction of CSC observed with VS-5584.
The role of PI3K isoforms and mTOR in the preferential targeting of CSC by VS-5584.
To further assess the contribution of individual PI3K isoforms and mTOR in mediating the CSC effect of VS-5584, SUM159 cells were transfected with siRNA specific for PI3Kα, PI3Kβ, or mTOR individually or in combination. Two different siRNA sequences were used per gene. An Aldefluor assay was carried out 3 days post siRNA transfection. PI3Kδ and PI3Kγ
were not examined because they are mostly expressed in leukocytes and their role in epithelial cells is not established (24) . Single isoform knock-down of PI3Kα, PI3Kβ or mTOR resulted in a moderate increase in the percentage of Aldefluor+ cells compared to scrambled control siRNA.
Importantly, double knockdown of PI3Kα and PI3Kβ, PI3Kα and mTOR or PI3Kβ and mTOR decreased the percentage of Aldefluor+ CSC to some extent, whereas triple knockdown of PI3Kα, PI3Kβ and mTOR, which mirrors the kinase inhibition profile of VS-5584, showed the most striking 70% reduction of the proportion of Aldefluor+ cells (Fig. 4A ). Effective target knockdown by all siRNAs was confirmed by western blot analysis (Fig. 4B) . These data further support the notion that inhibition of multiple components of the PI3K/mTOR pathway by VS-5584 is critical for the observed preferential targeting of CSC. 
Having demonstrated that VS-5584 preferentially reduced CSC in both cell line models and in vivo tumor xenografts, we determined if ex vivo treatment with VS-5584 preferentially targets CSC in surgically removed primary human tumor specimens. Ex vivo treatment of breast tumor tissue fragments with VS-5584 for 5 days reduced the proportion of both CD44 hi /CD24 lo ( Fig. 5A) and Aldefluor+ (Fig. 5B) CSC. The modest effect on the tumor of patient 3 (Fig. 5A-B ) may be explained by a sample quality issue, as there were significantly fewer live cells available for FACS analysis compared to tumors of patients 1 and 2 (Fig. 5A) . We reasoned that other carcinomas, such as ovarian cancer, might depend on similar CSC signaling pathways.
Accordingly, ex vivo treatment with VS-5584 was undertaken using ovarian tumor tissue, surgically removed from two patients who had received prior taxane-and platinum-based chemotherapy. Ex vivo treatment with 100 nM VS-5584 for 5 days reduced the proportion of (Fig. 6C ).
Subsequently, we sought to determine if VS-5584 can delay tumor regrowth after initial de-bulking by cisplatin, a standard-of-care first line chemotherapeutic agent, in human SCLC xenograft models. Prior to in vivo experiments, we confirmed that cisplatin or etoposide were not effective in depleting CSC of SCLC cell lines; in fact, both agents enriched CSC whereas VS-5584 depleted CSC in vitro (Fig. S3) . In the NCI-H69 SCLC xenograft study, weekly i.p. dosing of 5 mg/kg cisplatin for 2 weeks induced initial tumor regression, but these tumors regrew quickly after cessation of cisplatin treatment (26) . Single agent VS-5584 at 15 mg/kg dosed orally once daily caused significant inhibition of NCI-H69 tumor growth (p < 0.05). In combination, VS-5584 substantially delayed the regrowth of NCI-H69 tumors following cessation of cisplatin treatment (Fig. 6D) . Patient-derived-xenograft (PDX) models, which preserve the histology and heterogeneity of patient tumors, may be more relevant models for CSC research (27, 28) . We therefore tested VS-5584 in a SCLC PDX model established from a lymph node metastasis of a patient with SCLC. In keeping with our observations with the NCI- (Fig. 6E) . These results are consistent with the suppression of cisplatin-resistant CSC by VS-5584, resulting in a longer delay of tumor regrowth after cessation of cisplatin treatment.
Discussion
Intensive efforts have been devoted to targeting the PI3K/mTOR pathway due to its critical importance in the proliferation and survival of cancer cells. Here we report that, in addition to exhibiting broad and robust antitumor activity in animal models (15) , VS-5584, a potent dual PI3K/mTOR kinase inhibitor, also exerts a preferential effect on CSC present in cell culture, in human tumor xenografts, and in surgically excised human tumor specimens. In stark contrast, the cytotoxic chemotherapeutic agent paclitaxel, cisplatin and etoposide increased the proportion of CSC. Our observation that VS-5584 inhibited tumor regrowth after effective treatment with cisplatin in SCLC models, including a patient-derived primary tumor model, is consistent with the notion that VS-5584 may delay tumor recurrence at least in part through the suppression of CSC. To our knowledge, this is the first comprehensive evaluation of the effect of a highly selective PI3K/mTOR inhibitor on cancer stem cells.
The PI3K/mTOR pathway has been shown to be important for the proliferation of cancer stem cells in both solid tumors and leukemias (10) (11) (12) (13) (14) . In prostate cancer, a CD133 growth in a colon CSC-derived xenograft model (29) . However, in these various studies, a critical unanswered question remained whether PI3K/mTOR inhibitors exert a general antiproliferative effect against both CSC and non-CSC, or whether the CSC are more dependent on the PI3K/mTOR pathway than are non-CSC. Interestingly, Wicha and colleagues reported that the AKT inhibitor perifosine reduced the proportion of ALDH+ CSC as well as tumor-initiating cells in breast tumor models (13) , suggesting that perifosine has preferential effects on breast cancer stem cells. In light of the fact that perifosine was subsequently reported to also inhibit EGFR and c-Met phosphorylation (30) , the CSC effect of perifosine could be due to inhibition of these other molecular targets in addition to AKT.
VS-5584 is highly selective for Class I PI3K isoforms and mTOR kinase with no significant activity against over 400 other protein and lipid kinases profiled (15) . We provide clear evidence that inhibition of mTORC1, mTORC2 and PI3K isoforms by VS-5584 confers a strong preferential inhibitory effect on CSC across different carcinoma types, including breast, ovarian and small cell lung cancer. While VS-5584 preferentially abolished CSC in the MCF7 breast tumor model, an mTORC1-selective inhibitor everolimus did not reduce the proportion of CSC. Rapamycin, a closely related mTORC1 inhibitor, also did not impact the self-renewal of mammary stem cells (13) . These data therefore suggest that inhibiting PI3K isoforms, mTORC1 and mTORC2 simultaneously may be important to exert a strong preferential effect on CSC.
This hypothesis was further substantiated by our result that triple knockdown of PI3Kα, PI3Kβ, and mTOR by siRNA showed the strongest preferential reduction of CSC while knockdown of PI3Kα, PI3Kβ or mTOR individually did not exert a preferential effect on CSC (Fig. 4) . and platinum agents (e.g. cisplatin). While these agents may effectively de-bulk tumors and control disease initially, tumors invariably recur due to ineffective control of CSC. A CSCtargeting agent is expected to block CSC-mediated tumor recurrence. Our results generated using two SCLC xenograft models (Fig. 6) 10,000 3(4) 2(4) 3(4) 1,000 2(7) 0(7) 3(7) 100 0(7) 0(7) 1 
